Literature DB >> 12821824

Practical applications of viral fitness in clinical practice.

Michael Bates1, Terri Wrin, Wei Huang, Christos Petropoulos, Nicholas Hellmann.   

Abstract

PURPOSE OF REVIEW: To review recent clinical data regarding viral fitness and its potential utility in clinical practice. Therapeutic failure of antiretroviral regimens is often due to the development of drug resistance. The viral loads achieved by these drug-resistant variants frequently remain suppressed below pretreatment levels. Furthermore, many patients with virologic failure continue to maintain stable CD4 counts and remain clinically well. One possible explanation for these observations is that the resistant virus that emerges during failure of highly active antiretroviral therapy is less fit than its wild-type counterpart as a result of the requirement to maintain resistance mutations that allow it to replicate in the presence of antiretroviral drugs. Since there are many patients with limited treatment options due to extensive resistance or drug toxicities, or both, there is intense interest in exploring the possibility that viral fitness can be exploited for clinical benefit. This review describes the assays that are used to measure fitness and replication capacity, and investigations of their utility in clinical practice. RECENT
FINDINGS: A number of methods have been developed to measure viral fitness. Replication kinetic and competitive culture assays are accurate, but labour and time intensive. The availability of a rapid, single-cycle recombinant assay that measures viral replication capacity presents the possibility that assessments of viral fitness could be incorporated into clinical management. The replication capacity assay appears to correlate with more standard measures of viral fitness, and recently accumulated data in both wild-type and drug resistant viral populations suggest that replication capacity describes an intrinsic characteristic of HIV-1. A number of investigations of the clinical utility of fitness and replication capacity assays have established correlations between these measurements and virologic and immunologic outcomes.
SUMMARY: Much progress has been made in the past year in our understanding of viral fitness and replication capacity. Assays that measure these viral characteristics have the potential to expand the range of clinical strategies employed against HIV-1. Further investigations are needed to firmly establish the clinical utility of these assays.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821824     DOI: 10.1097/00001432-200302000-00003

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  10 in total

1.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Differential impact of resistance-associated mutations to protease inhibitors and nonnucleoside reverse transcriptase inhibitors on HIV-1 replication capacity.

Authors:  Szu-Min Hsieh; Sung-Ching Pan; Sui-Yuan Chang; Chien-Ching Hung; Wang-Huei Sheng; Mao-Yuan Chen; Shan-Chwen Chang
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-15       Impact factor: 2.205

3.  Dendritic cell-mediated HIV-1 infection of T cells demonstrates a direct relationship to plasma viral RNA levels.

Authors:  Reetakshi Arora; Lara Bull; Edward B Siwak; Rajesh Thippeshappa; Roberto C Arduino; Jason T Kimata
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

4.  Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

5.  Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.

Authors:  Sabine Lohrengel; Felix Hermann; Isabel Hagmann; Heike Oberwinkler; Laura Scrivano; Caroline Hoffmann; Dorothee von Laer; Matthias T Dittmar
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.

Authors:  Brian J Skaggs; Mercedes E Gorre; Ann Ryvkin; Michael R Burgess; Yongming Xie; Yun Han; Evangelia Komisopoulou; Lauren M Brown; Joseph A Loo; Elliot M Landaw; Charles L Sawyers; Thomas G Graeber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-12       Impact factor: 11.205

Review 7.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

8.  HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.

Authors:  Matthew Bidwell Goetz; Robert Leduc; Nicole Wyman; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04-01       Impact factor: 3.731

9.  Infectivity of Homologous Recombinant HIV-1 Pseudo-virus with Reverse Transcriptase Inhibitor-related Mutations from Highly Active Antiretroviral Therapy Experienced Patients.

Authors:  Oh-Kyung Kwon; Ju-Yeon Choi; Eun-Jin Kim; Sung Soon Kim
Journal:  Osong Public Health Res Perspect       Date:  2011-04-14

Review 10.  Microbicides for the Treatment of Sexually Transmitted HIV Infections.

Authors:  Onkar Singh; Tarun Garg; Goutam Rath; Amit K Goyal
Journal:  J Pharm (Cairo)       Date:  2014-02-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.